Curia
Curia is a global CDMO with 3,000+ employees and 20+ facilities providing integrated drug discovery, development, and manufacturing services across small molecule, generic APIs, biologics, and sterile drug products for biopharmaceutical companies worldwide.
- Company typePrivate
- Founded1990
- HeadquartersAlbany, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Curia does
Curia Global, Inc. is a privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Albany, New York, operating 20+ facilities across North America, Europe, and India with a workforce of 3,000+ professionals. Founded in 1990 as the first CRO to offer contract medicinal chemistry services, the company has evolved into an integrated CDMO providing services across four business segments: Small Molecule (discovery through commercial manufacturing), Generic APIs (150+ products from 12 GMP facilities), Biologics (antibody discovery through GMP mammalian and mRNA manufacturing), and Sterile Drug Product (clinical and commercial fill-finish for vials and prefilled syringes).
Curia's core technology platform spans proprietary flow chemistry with continuous processing capabilities, aseptic API manufacturing via closed-system isolators, fermentation from 2L to 48,000L scale, high-potency manufacturing (SafeBridge-certified for OELs below 0.1 ug/m3), and industrial chromatography from 100mL development columns to 500L commercial scale. The biologics offering includes an IP-free semi-targeted integration cell line development platform delivering 6-fold higher titers, mRNA and LNP formulation services, and GMP mammalian drug substance manufacturing. The company has filed 550+ API Drug Master Files worldwide with approvals from FDA, EMA, PMDA, KFDA, ANVISA, MHRA, and AIFA, and holds patented processes for high-value APIs including Olopatadine HCl, Etrasimod Arginine, Upadacitinib, and Deucravacitinib.
Curia's business model is fee-for-service CDMO contracts (multi-year engagements) complemented by catalog sales of generic APIs and fine chemicals (T3P reagent, vinylphosphonic acid, oxa acids, boronic acids, Gemagique AMPS polymers). The company employs an enterprise field sales motion targeting biopharmaceutical companies and generic drug manufacturers through direct engagement, industry events, and technical content marketing. Customers include 300+ sterile API clients across 30+ countries. The company is backed by private equity investor GTCR (since 2017) and completed strategic refinancing in March 2025 alongside a $200M multi-year investment in sterile fill-finish capacity expansion targeting GLP-1 and biologic demand.
Curia firmographics
Firmographics- Name
- Curia
- Legal name
- Curia Global, Inc.
- Website
- https://curiaglobal.com
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Curia is a global CDMO with 3,000+ employees and 20+ facilities providing integrated drug discovery, development, and manufacturing services across small molecule, generic APIs, biologics, and sterile drug products for biopharmaceutical companies worldwide.
- Ownership category
- akta.pro rank
Curia industry classification
Industry- Product category
- Contract Pharmaceutical Manufacturing Services
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Chemical Manufacturing (325)
- SIC
- Industrial Organic Chemicals (2860)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule API & Intermediates CDMO (HLAGABAA), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where Curia is headquartered
LocationHeadquarters
- HQ city
- Albany
- HQ country
- United States
- HQ region
- North America
Offices18 records
Markets served
Curia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Development and Manufacturing Services: Curia operates as a CDMO providing integrated services across drug discovery, development, and manufacturing. Revenue is generated through fee-for-service contracts for pharmaceutical companies requiring API manufacturing, sterile fill-finish, biologics manufacturing, and related services. Services are offered across clinical trial materials through commercial scale production.
- Generic API Sales: Sale of off-patent active pharmaceutical ingredients from an extensive catalog of 150+ generic APIs covering multiple therapeutic areas including steroids, hormones, and controlled substances
- Fine Chemicals: Sale of specialty fine chemicals including T3P reagent, vinylphosphonic acid, oxa acids, and boronic acids for pharmaceutical, agrochemical, and industrial applications
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing for CDMO services |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Curia product offering
Product offeringCore offering
Curia is a global Contract Development and Manufacturing Organization (CDMO) providing integrated drug discovery, development, and manufacturing services across four business units: Small Molecule, Generic APIs, Biologics, and Sterile Drug Product. The company serves biopharmaceutical clients with capabilities spanning discovery biology, medicinal chemistry, flow chemistry, fermentation, fill-finish, and commercial API manufacturing across 20+ facilities in the US, Europe, and India. It also manufactures and sells specialty fine chemicals including T3P reagent and proprietary polymers.
Product overview
Curia is a global Contract Development and Manufacturing Organization (CDMO) offering integrated services across four core business units: Small Molecule Services (spanning discovery through commercial manufacturing), Generic APIs (150+ products from 12 GMP facilities), Biologics Services (from antibody discovery through GMP mammalian and mRNA manufacturing), and Sterile Drug Product Services (clinical and commercial fill-finish). The company also manufactures and sells Fine Chemicals including T3P® reagent, Vinylphosphonic Acid, Oxa Acids, 4-FPBA, and Gemagique® polymers. Supporting capabilities include High Potency API manufacturing, Sterile API manufacturing, Steroids & Hormones production, Industrial Chromatography, Flow Chemistry, Fermentation, and Controlled Substances manufacturing. With over 30 years of experience and 20+ facilities across North America, Europe, and India, Curia provides end-to-end solutions from early drug discovery through commercial manufacturing.
Differentiator
Problem solved
Functional benefit
Brands
- Gemagique® AMPS Polymers: Cutting-edge AMPS-based polymers designed for cosmetics, personal care, and home care industries
- T3P® Reagent
Products and services
- Small Molecule Services Integrated small molecule drug discovery, development, and cGMP API manufacturing services including assay development, medicinal chemistry, DMPK, computer-aided drug design (CADD), custom synthesis, flow chemistry, high potency, sterile API, steroids and hormones, fermentation, industrial chromatography, and GMP controlled substance manufacturing. Serves pharmaceutical companies from clinical trials through commercial scale.
- Generic APIs Off-patent active pharmaceutical ingredients from a portfolio of 150+ generic APIs covering multiple therapeutic areas including steroids, hormones, and controlled substances. Manufactured across 12 GMP facilities in the US, France, Italy, Spain, and India.
- Biologics Services Comprehensive biologics capabilities from discovery through GMP manufacturing including antibody discovery and engineering, mammalian cell line development with IP-free semi-targeted integration technology, mRNA services, LNP formulation, and GMP mammalian and mRNA drug substance manufacturing.
- Sterile Drug Product Services Clinical and commercial sterile drug product manufacturing including formulation development, process development, clinical manufacturing, and commercial manufacturing. Capabilities for complex and viscous formulations, vials, and prefilled syringes across facilities in Burlington (MA), Albuquerque (NM), and Glasgow (UK).
- Analytical Testing Services Comprehensive analytical services including batch release and stability testing, method development and validation, and solid state chemistry. Supports drug substance and drug product testing across all development phases.
- T3P® Reagent (Propane-phosphonic Acid Anhydride) Propane-phosphonic acid anhydride reagent for condensation reactions including amide and peptide bond formation. Non-toxic, non-allergenic reagent with high selectivity, minimal epimerization, and exceptional product yields. ISO 9001:2015 certified production in Frankfurt, Germany.
- Gemagique® AMPS Polymers AMPS-based polymers (Ammonium Polyacryloyl Dimethyl Taurate) for cosmetics, personal care, and home care industries. Products include Gemagique HP, HPS, and CP1 with applications in creams, lotions, gels, and emulsions.
- Oxa Acids Environmentally friendly biodegradable compounds with lipophilic and hydrophilic functionalities for pharmaceuticals, cosmetics, and nanotechnology. Products include DOODS, TODS, and TUDS with applications in drug delivery, emulsifiers, and high-tech materials.
- Vinylphosphonic Acid (VPA) Innovative compound with over 20 years of production expertise for surface treatment, adhesion promotion, dispersion stability, flame retardancy, and fuel cells. VPA-based co-polymers improve proton exchange membranes for energy efficiency.
- 4-Formylphenyl Boronic Acid (4-FPBA) Versatile chemical used in detergent, pharmaceutical, and agrochemical sectors. Produced in cGMP-approved facility in Europe with capacity of several hundred tons annually. Patented manufacturing process ensures high purity for enzyme stabilization and drug synthesis.
Quantifiable outcome
- 300+ sterile API clients in 30+ countries
- +2 more outcomes
Companies that use Curia
Customer profileSegments2 records
Ideal customer profiles2 records
Curia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Curia partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Apprentice.iocoreCuria expanded its partnership with Apprentice.io by selecting Apprentice as the MES (Manufacturing Execution System) platform for its Albuquerque, New Mexico site, following a successful deployment at its Rensselaer, New York facility. The expansion reflects Curia's continued investment in digital manufacturing capabilities aimed at driving greater efficiency, data visibility, and operational consistency across its network. The partnership includes access to Apprentice.io's manufacturing-specific AI agents, including their A1 autonomous AI agent designed for pharmaceutical and biotech manufacturing workflows.
Scale indicators16 records
Recent moves8 records
Expansion highlights6 records
Curia competitors and assessment
Company assessmentDirect peers
- Siegfried Holding: Swiss-headquartered CDMO specializing in small molecule API manufacturing including controlled substances, steroids, and high potency. Closely comparable to Curia's small molecule API and generics business.
- Lonza Group: Global CDMO leader offering integrated small molecule and biologics services including API manufacturing, biologics, and cell and gene therapy. Directly comparable as a full-service CDMO across multiple modalities.
- Recipharm: European CDMO offering small molecule API manufacturing, sterile fill-finish, and biologics. Comparable mid-sized peer with similar service breadth and geographic footprint.
- Catalent (Novo Holdings): Major CDMO with deep capabilities in sterile fill-finish, biologics, and oral dose manufacturing. Highly comparable given Curia's recent $200M+ sterile fill-finish expansion directly competing for the same client base.
- Aenova Group: European CDMO focused on solid oral dosage forms, sterile fill-finish, and API manufacturing. Comparable in solid dose and sterile drug product capabilities.
- WuXi AppTec / WuXi Biologics: China-headquartered global CDMO offering small molecule API, biologics, and integrated discovery through manufacturing services. Direct competitor across Curia's full service stack.
- Samsung Biologics: Large-scale biologics CDMO with substantial mammalian cell culture capacity. Comparable for Curia's biologics manufacturing expansion targeting commercial-stage biologic and GLP-1 demand.
- Piramal Pharma Solutions: Global CDMO offering integrated API and drug product services across small molecules, including high potency and sterile manufacturing. Comparable as a similarly scaled multi-modality CDMO.
- Eurofins CDMO (Eurofins Discovery): Eurofins operates a CDMO franchise spanning small molecule discovery, development, and API manufacturing. Comparable in early discovery through clinical stage services.
Broad incumbents
- Thermo Fisher Scientific (Patheon CDMO): Through its Patheon CDMO business, Thermo Fisher offers comprehensive small molecule and biologics services globally. A larger diversified incumbent competing across Curia's entire portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Curia social profiles
Digital presenceCuria compliance and trust
Trust signalCompliance5 records
Curia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Curia leadership team
Management profileNumber of profiles
Profiles4 records
Curia funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Curia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Curia
What does Curia do?
Curia is a global Contract Development and Manufacturing Organization (CDMO) providing integrated drug discovery, development, and manufacturing services across four business units: Small Molecule, Generic APIs, Biologics, and Sterile Drug Product. The company serves biopharmaceutical clients with capabilities spanning discovery biology, medicinal chemistry, flow chemistry, fermentation, fill-finish, and commercial API manufacturing across 20+ facilities in the US, Europe, and India. It also manufactures and sells specialty fine chemicals including T3P reagent and proprietary polymers.
Is Curia a public or private company?
Curia is a private company. It is classified as private equity controlled and is currently operating.
When was Curia founded?
Curia was founded in 1990. It employs 1,001 to 5,000 people.
Where is Curia based?
Curia is headquartered in Albany, United States, in the North America region.
How does Curia make money?
Three revenue lines are on record. Contract Development and Manufacturing Services are the primary driver. The others are generic API Sales and fine Chemicals.
Who are Curia's main competitors?
Direct peers on record are Siegfried Holding, Lonza Group, Recipharm, Catalent (Novo Holdings), Aenova Group, WuXi AppTec / WuXi Biologics, Samsung Biologics, Piramal Pharma Solutions and Eurofins CDMO (Eurofins Discovery). Thermo Fisher Scientific (Patheon CDMO) is listed as a broad incumbent.
Does Curia have an API?
No public API is recorded for Curia.
What industry is Curia in?
Curia's product category is Contract Pharmaceutical Manufacturing Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 3254 and its SIC code is 2860.